.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Queensland Health
Medtronic
Merck
US Army
Covington
Federal Trade Commission
Argus Health
Healthtrust

Generated: November 19, 2017

DrugPatentWatch Database Preview

Deutetrabenazine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for deutetrabenazine and what is the scope of deutetrabenazine freedom to operate?

Deutetrabenazine
is the generic ingredient in one branded drug marketed by Teva Branded Pharm and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Deutetrabenazine has twenty-nine patent family members in eleven countries.

One supplier is listed for this compound.

Summary for deutetrabenazine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-003Apr 3, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-002Apr 3, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-001Apr 3, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-003Apr 3, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-003Apr 3, 2017RXYesYes► Subscribe► SubscribeY ► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-002Apr 3, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-001Apr 3, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-002Apr 3, 2017RXYesNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-001Apr 3, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-003Apr 3, 2017RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: deutetrabenazine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,346,800Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: deutetrabenazine

Country Document Number Estimated Expiration
Hong Kong1186728► Subscribe
European Patent Office2326643► Subscribe
Japan2015007124► Subscribe
Spain2425623► Subscribe
Japan5970037► Subscribe
European Patent Office2897615► Subscribe
China104311552► Subscribe
Japan6138322► Subscribe
Canada2972242► Subscribe
Australia2013318182► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Chinese Patent Office
Cipla
Queensland Health
Argus Health
Medtronic
Chubb
Healthtrust
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot